TSR

WisdomTree Board of Directors Sends Letter to Graham Tuckwell in Response to Mr. Tuckwell’s February 20 Letter to the Board

Retrieved on: 
Tuesday, February 27, 2024
Blockchain, Finance, Asset Management, Professional Services, Technology, Fintech, Digital Cash Management, Digital Assets, Business, ETF Securities, Acquisition, European, Growth, TSR, AUM, Letter, ETF, Audit committee, Judgement, WisdomTree Investments, Trust, Management

You also proposed that the Board immediately form a special committee of independent directors and publicly announce an expeditious strategic review of the entire business.

Key Points: 
  • You also proposed that the Board immediately form a special committee of independent directors and publicly announce an expeditious strategic review of the entire business.
  • This Board believes that if we were to implement your proposals, it would jeopardize WisdomTree’s success and harm the Company and its stockholders.
  • This trust was further evidenced by the Board’s recent unanimous approval of both the 2024 annual budget and 2023 performance compensation.
  • We urge you to respect the will of our stockholders and the judgment of our Board.

Concerned Stockholders of Nikola Corp. Introduce Slate of Independent Director Candidates for Election to the Company’s Board at the 2024 Annual Meeting

Retrieved on: 
Tuesday, February 20, 2024
Professional Services, Automotive, Automotive Manufacturing, EV, Electric Vehicles, Manufacturing, Finance, Engineering, Iveco, Certificate, Sale, University, PLLC, M&M, Supply chain management, Concerned, Social media, Transport, Business administration, Security (finance), Brigham Young University, Partnership, Common stock, WHEN, Shop, Safety, Authorization, Business, Chair, Marriott School, Marketing, TSR, Entrepreneurship, Risk, WAV, Nikola Corporation, UPON, Management

Today, the Concerned Stockholder Group issued the below statement regarding its nomination of five highly qualified and independent director candidates for election to the Company’s nine-member Board of Directors (the “Board”) at the 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”).

Key Points: 
  • Today, the Concerned Stockholder Group issued the below statement regarding its nomination of five highly qualified and independent director candidates for election to the Company’s nine-member Board of Directors (the “Board”) at the 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”).
  • Our slate of director candidates is highly qualified, wholly independent and focused on one goal: implementing a lasting turnaround that unlocks the significant potential of Nikola.
  • In fact, our Group has been approached by numerous stockholders who want to see CEO Steve Girsky and his Board replaced with high-integrity individuals.
  • TSR includes dividends reinvested using a closing price of February 8, 2024, the day before Nikola made the Group’s nomination public.

JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval

Retrieved on: 
Tuesday, March 5, 2024
Senior, Tenderness, Infection, Dizziness, AbbVie, XC, Lidocaine, Swelling, Exercise, Skin, Pregnancy, History, Cyst, Red, HIV/AIDS, Trial of the century, Allergy, Social media, Incidence, Neck, Dermatology, Aspirin, Pain, Forehead, Stroke, Hyaluronic acid, Pimple, Pigment, Ibuprofen, Scar, Rash, Anaphylaxis, Chin, Learning, Weakness, Safety, Filler (linguistics), DSM-IV codes, Hypoesthesia, Clinical trial, Paratriathlon, Bleeding, Face, Jaw, ABBV, Injection, Bruise, AMI, Inflammation, FDA, TSR, U.S. FDA, Confusion, Risk, Steroid, Patient, Tell, Wound, Gram, HIV, Cheek

IRVINE, Calif., March 5, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUMA® XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21.1 JUVÉDERM® VOLUMA® XC is the first and only hyaluronic acid (HA) dermal filler to receive U.S. FDA approval for the improvement of moderate to severe temple hollowing with results lasting up to 13 months with optimal treatment.*1

Key Points: 
  • *1
    "The approval of JUVÉDERM® VOLUMA® XC to treat temple hollows further demonstrates Allergan Aesthetics commitment to innovation and addressing patient needs," said Carrie Strom, President, Allergan Aesthetics and Senior Vice President, AbbVie.
  • "This is the first U.S. FDA approval of a hyaluronic acid dermal filler for use in the upper face and addresses a real unmet need for patients."
  • The safety of JUVÉDERM® VOLUMA® XC in patients with a history of excessive scarring or pigmentation disorders has not been studied.
  • To report a side effect with any product in the JUVÉDERM® Collection, please call the Allergan® Product Support Department at 1‑877‑345‑5372.

Kamux Corporation's Financial Statements Bulletin for January 1--December 31, 2023: Revenue grew and adjusted operating profit increased significantly during the fourth quarter

Retrieved on: 
Friday, March 1, 2024
Reward, EV, Plan, Shareholder, Person, Nasdaq Helsinki, Capital market, Annual report, Financial statement, Investment, Sanomatalo, Strategic planning, TSR, ID, ESG, Chairperson, Q3, EUR, AGM, Tax, Employment, Electricity, News, ESP, Remuneration, Trust, Corporation, Annual, Communication

HÄMEENLINNA, Finland, March 1, 2024 /PRNewswire/ -- Kamux Corporation's Financial Statements Bulletin for January 1—December 31, 2023: Revenue grew and adjusted operating profit increased significantly during the fourth quarter

Key Points: 
  • In the last quarter of the year, our revenue grew by 8.4% and was EUR 242 million.
  • As a result of the good gross profit development, our adjusted operating profit developed positively despite being burdened by e.g.
  • The Group's adjusted operating profit was EUR 5.5 million (+164%) in the fourth quarter and EUR 18.0 million (+3.2%) for the whole year.
  • Kamux expects its adjusted operating profit for 2024 to exceed its 2023 adjusted operating profit, which was EUR 18.0 million.

Kamux's share-based incentive plan for 2024-2026

Retrieved on: 
Friday, March 1, 2024
Reward, Plan, Person, Nasdaq Helsinki, TSR, ESG, EUR, Employment, Tax, ESP, Corporation, Management

HÄMEENLINNA, Finland , March 1, 2024 /PRNewswire/ -- 

Key Points: 
  • Kamux Corporation's Board of Directors has decided to approve a new long-term incentive Plan for the Group's key persons for 2024–2026 (the "Plan").
  • The Board of Directors has selected 38 key persons, including the CEO, to participate in the Plan.
  • In accordance with the terms and conditions of the Plan, the Board of Directors may decide during the performance period on the admission of new participants to the Plan.
  • The Board of Directors has resolved that the above-mentioned long-term share-based incentive plan for the CEO will be discontinued as of January 1, 2024 and that CEO Tapio Pajuharju will participate in the company's new share-based incentive plan described above as of January 1, 2024 (the "Plan").

Notice of Ericsson's Annual General Meeting 2024

Retrieved on: 
Wednesday, February 28, 2024
Transfer, Person, Travel, Greenhouse, Nasdaq Stockholm, Annual report, F5, Inc., Cisco, Peer group, Corporation, Bank statement, Equity swap, IBM, Ethics, Participation, Compensation, Section 31, Swedish, Social Security, Treasury, Companies Act, Remuneration, Guideline, Chapter Four, Executive, Woman, Committee, Motorola Solutions, Calendar, ESG, LTV, Carbon, Business travel, Employment, Carbon accounting, GHG, Acquisition, KC, Air travel, Note, TSR, CGI Inc., Investor AB, AGM, Annual, Security (finance)

Information about the outcome of the performance criteria will be provided no later than in the annual report for the financial year 2026.

Key Points: 
  • Information about the outcome of the performance criteria will be provided no later than in the annual report for the financial year 2026.
  • The new shares shall be subscribed for during the period as from April 25, 2024, up to and including May 2, 2024.
  • The Company has decided to implement one other share-related compensation program for 2024: the Key Contribution Plan 2024 ("KC Plan 2024").
  • The new shares shall be subscribed for during the period as from April 25, 2024, up to and including May 2, 2024.

Notice of Ericsson's Annual General Meeting 2024

Retrieved on: 
Wednesday, February 28, 2024
Transfer, Person, Travel, Greenhouse, Nasdaq Stockholm, Annual report, F5, Inc., Cisco, Peer group, Corporation, Bank statement, Equity swap, IBM, Ethics, Participation, Compensation, Section 31, Swedish, Social Security, Treasury, Companies Act, Remuneration, Guideline, Chapter Four, Executive, Woman, Committee, Motorola Solutions, Calendar, ESG, LTV, Carbon, Business travel, Employment, Carbon accounting, GHG, Acquisition, KC, Air travel, Note, TSR, CGI Inc., Investor AB, AGM, Annual, Security (finance)

Information about the outcome of the performance criteria will be provided no later than in the annual report for the financial year 2026.

Key Points: 
  • Information about the outcome of the performance criteria will be provided no later than in the annual report for the financial year 2026.
  • The new shares shall be subscribed for during the period as from April 25, 2024, up to and including May 2, 2024.
  • The Company has decided to implement one other share-related compensation program for 2024: the Key Contribution Plan 2024 ("KC Plan 2024").
  • The new shares shall be subscribed for during the period as from April 25, 2024, up to and including May 2, 2024.

DFIN Reports Fourth-Quarter and Full-Year 2023 Results

Retrieved on: 
Tuesday, February 20, 2024
XBRL, EDGAR, Investment, Marketing, Growth, Table, TSR, Communications management, GAAP, Webcast, Acceleration, DFIN, Exhibit, Mutual fund, Donnelley Financial Solutions, Video game

CHICAGO, Feb. 20, 2024 /PRNewswire/ -- Donnelley Financial Solutions, Inc. (NYSE: DFIN) (the "Company" or "DFIN") today reported financial results for the fourth quarter and full year of 2023.

Key Points: 
  • CHICAGO, Feb. 20, 2024 /PRNewswire/ -- Donnelley Financial Solutions, Inc. (NYSE: DFIN) (the "Company" or "DFIN") today reported financial results for the fourth quarter and full year of 2023.
  • Gross leverage(a) of 0.6x and net leverage(a) of 0.5x as of December 31, 2023.
  • Leib continued, "Throughout 2023, the focused execution of our strategy enabled us to achieve solid financial and operational results, in light of challenging market conditions.
  • DFIN will hold a conference call and webcast on February 20, 2024, at 9:00 a.m. Eastern time to discuss financial results for the fourth quarter of 2023, provide a general business update and respond to analyst questions.

Ventas Reports 2023 Full Year Results and Provides 2024 Outlook

Retrieved on: 
Wednesday, February 14, 2024
Commercial Building & Real Estate, Construction & Property, Seniors, Finance, REIT, Professional Services, Other Health, Managed Care, Consumer, Health, FFO, SHOP, Gold Award, Growth, TSR, Ventas, Health care, NOI, HHS, IRR, GAAP, Autumn, Inclusion, Equity, Ardent Health Services, Normalization, Brookdale Senior Living, Operation

A description of full year 2023 results is as follows:

Key Points: 
  • A description of full year 2023 results is as follows:
    2023 Net (Loss) Income Attributable to Common Stockholders per share increased $0.02 compared to 2022.
  • 2023 Total Company Net Operating Income* (“NOI”) increased year-over-year by 4.5% and Total Company Same-Store Cash NOI* was 8.1% higher year-over-year.
  • Successful Execution of Equitized Loan Portfolio Transaction: Ventas successfully took ownership of and integrated the collateral for the “Santerre” mezzanine loan.
  • Ventas expects to report 2024 per share Attributable Net Income to common stockholders, Nareit FFO and Normalized FFO within the following ranges:

Banco Santander-Chile Announces Fourth Quarter 2023 Earnings

Retrieved on: 
Friday, February 2, 2024
Pillar, BSAC, CHF, Growth, Central bank, ESG, Travel, NPS, Quarter, CLP, Daiwa Securities Group, Acceleration, Column, Government, SME, JPY, Banco Santander, COVID-19, DJSI, Environment, Banco Santander Chile, Investment banking, YTD, NPL, KBRA, Corporation, NII, NIM, S&P Global Ratings, Credit, Bank, Behavior, Moody's Investors Service, Retail banking, Central Bank of Myanmar, CIB, Life, Drainage, RWA, FMC, BIS, ADR, Yoy, Japan Credit Rating Agency, Insurance, MPR, TSR, Cryptocurrency

SANTIAGO, Chile, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Banco Santander Chile (NYSE: BSAC; SSE: Bsantander) announced today its resultsi for the twelve-month period ended December 31, 2023, and fourth quarter 2023 (4Q23).

Key Points: 
  • SANTIAGO, Chile, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Banco Santander Chile (NYSE: BSAC; SSE: Bsantander) announced today its resultsi for the twelve-month period ended December 31, 2023, and fourth quarter 2023 (4Q23).
  • As of December 31, 2023 our NPS reached 60 points, and our contact center reached 72 points, being recognized as the best in the industry.
  • Our CET1 ratio remains solid at 11.1% and the total Basel III ratio reaches 17.6% at the end of December 2023.
  • Our earnings webcast will be held on Friday, February 2, 2023 at 8.30am New York time.